Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy

Immunotherapy

Volumn 5, Issue 6, 2013, Pages 565-567

  Simon, Thomas ^a,b   Fonteneau, Jean François ^b,c   Grégoire, Marc ^b,c  

^a Groupe de Recherche Cytokines et Récepteurs en Immuno Cancérologie   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UMR 6299   (France)

Author keywords

antitumor immunotherapy; cytotoxic T cell; dendritic cells; helper T cell; melanoma; tumor associated antigen

Indexed keywords

DACARBAZINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; IMMUNE RESPONSE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; MALE; MELANOMA; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84878724499     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.45     Document Type: Article

References (17)

1. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012).
2. Simon T, Fonteneau JF, Gregoire M. Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy 1(2), 289-302 (2009).
3. Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin. Cancer Res. 12(7 Pt 2), S2342-S2345 (2006).
4. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 328-332 (1998).
5. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190(11), 1669-1678 (1999).
6. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10(5), 588-594 (1998).
7. Aarntzen EH, De Vries IJ, Lesterhuis WJ et al. Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 73(1), 19-29 (2013).
8. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684), 478-480 (1998).
9. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393(6684), 474-478 (1998).
10. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393(6684), 480-483 (1998).
11. Lanzavecchia A. Immunology. Licence to kill. Nature 393(6684), 413-414 (1998).
12. Simon T, Tanguy-Royer S, Royer PJ et al. Human dendritic cells sequentially matured with CD4+ T cells as a secondary signal favor CTL and long-term T memory cell responses. Biol. Res. 45(1), 33-43 (2012).
13. Fearon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60(3), 397-403 (1990).
14. Larrieu P, Ouisse LH, Guilloux Y, Jotereau F, Fonteneau JF. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes. Cancer Immunol. Immunother. 56(10), 1565-1575 (2007).
15. Wang LX, Shu S, Disis ML, Plautz GE. Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 109(11), 4865-4876 (2007).
16. Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J. Immunol. 180(5), 3122-3131 (2008).
17. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J. Clin. Oncol. 29(21), 2924-2932 (2011).